Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016

References

1. Takashita E, Ejima M, Itoh R, Miura M, Ohnishi A, Nishimura H, et al. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill. 2014;19(1):20666.  https://doi.org/10.2807/1560-7917.ES2014.19.1.20666  PMID: 24434172 
2. Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, et al. Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan. Antimicrob Agents Chemother. 2015;59(5):2607-17.  https://doi.org/10.1128/AAC.04836-14  PMID: 25691635 
3. Nakauchi M, Ujike M, Obuchi M, Takashita E, Takayama I, Ejima M, et al. influenza virus surveillance group of Japan. Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay. J Med Virol. 2011;83(7):1121-7.  https://doi.org/10.1002/jmv.22101  PMID: 21567417 
4. Takashita E, Fujisaki S, Kishida N, Xu H, Imai M, Tashiro M, et al. Influenza Virus Surveillance Group of Japan. Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan. Influenza Other Respi Viruses. 2013;7(6):1390-9.  https://doi.org/10.1111/irv.12132  PMID: 23745712 
5. Nguyen HT, Nguyen T, Mishin VP, Sleeman K, Balish A, Jones J, et al. Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011. Emerg Infect Dis. 2013;19(12):1963-71.  https://doi.org/10.3201/eid1912.130705  PMID: 24274711 
6. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012;87(39):369-74. PMID: 23061103 
7. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis. 2012;206(2):148-57.  https://doi.org/10.1093/infdis/jis337  PMID: 22561367 
8. Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, et al. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog. 2014;10(4):e1004065.  https://doi.org/10.1371/journal.ppat.1004065  PMID: 24699865 
9. Abed Y, Pizzorno A, Bouhy X, Rhéaume C, Boivin G. Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets. J Virol. 2014;88(3):1652-8.  https://doi.org/10.1128/JVI.02681-13  PMID: 24257597 
10. Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res. 2015;117:27-38.  https://doi.org/10.1016/j.antiviral.2015.02.003  PMID: 25721488 
11. Hooper KA, Bloom JD. A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein. J Virol. 2013;87(23):12531-40.  https://doi.org/10.1128/JVI.01889-13  PMID: 24027333 
12. Hooper KA, Crowe JE Jr, Bloom JD. Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice. J Virol. 2015;89(7):3737-45.  https://doi.org/10.1128/JVI.00012-15  PMID: 25609803 
13. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006;443(7107):45-9.  https://doi.org/10.1038/nature05114  PMID: 16915235 
14. Wu Y, Qin G, Gao F, Liu Y, Vavricka CJ, Qi J, et al. Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding. Sci Rep. 2013;3:1551.  https://doi.org/10.1038/srep01551  PMID: 23531861 
15. Molecular Operating Environment (MOE). 2013.08; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2016.
16. Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, et al. WHO Consultation on Pandemic Influenza A (H1N1) 2009 Virus Resistance to Antivirals. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2012;12(3):240-8.  https://doi.org/10.1016/S1473-3099(11)70318-8  PMID: 22186145 
17. Renaud C, Boudreault AA, Kuypers J, Lofy KH, Corey L, Boeckh MJ, et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis. 2011;17(4):653-60, quiz 765.  https://doi.org/10.3201/eid1704.101429  PMID: 21470455 
18. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis. 2010;51(8):983-4.  https://doi.org/10.1086/656439  PMID: 20858074 
19. Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, Phuah SP, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill. 2011;16(23):19884. PMID: 21679678